Actively Recruiting

All Genders
ID05713214

Long-term Follow-up After Adoptive Transfer of Genetically Modified Cell Products

Led by St. Jude Children's Research Hospital · Updated on 2026-05-26

1000

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are conducting a long-term follow-up study to monitor people who have received gene therapy products that modify human cells genetically. This study focuses on participants treated in St. Jude investigator-initiated clinical trials for relapsed or refractory blood cancers. The goal is to detect any significant delayed medical effects after receiving these gene therapies, following FDA guidelines for safety monitoring. Participants join this observational study after completing the initial clinical trial where they received a genetically modified cell product. There are no treatment groups, placebos, or control subjects in this study. The follow-up lasts up to 15 years post-infusion of the gene therapy product, with assessments conducted routinely over this time. During the study, participants will undergo regular evaluations including medical history reviews, physical exams, and blood sample collections. These assessments may be done locally in coordination with the St. Jude research team. Researchers will also review existing clinical data related to the participant's prior gene therapy treatment, including disease history, current status, treatments after gene therapy, relapse, and survival. The primary outcome is gathering detailed histories to identify any delayed medical issues over 30 years.

CONDITIONS

Brief Title

Long-term Follow-up After Adoptive Transfer of Genetically Modified Cell Products

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Receipt of a genetically modified cell product on a St. Jude investigator-initiated study within the prior 15 years.
Not Eligible

You will not qualify if you...

  • Inability or unwillingness of research participant and/or legal guardian/ representative to give written informed consent.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person or local provider)

Long-term Monitoring

Duration - Up to 15 years post infusion

Participants undergo routine history, physical exams, and blood sample collections to monitor long-term effects after gene therapy treatment. Assessments may be done by a local provider in conjunction with the research team.

Periodic visits as coordinated with the research team and local providers

Trial Site Locations

Total: 1 location

1

St. Jude Children's Research Hospital

Memphis, Tennessee, United States, 38105

Actively Recruiting

Loading map...

Research Team

A

Aimee Talleur, MD

S

Swati Naik, MBBS

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

A Phase Ia/Ib Open-label Dose Escalation and Expansion Study...

Advanced Solid Tumors

Actively Recruiting

8 locations

Open-Label Dose Escalation and Expansion Trial of Emavuserti...

Relapsed Hematologic Malignancy

Actively Recruiting

45 locations

International Concerted Action to Allocate Children, Adolesc...

Relapsed Hematologic Malignancy

Actively Recruiting

7 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here